Canaccord raised the firm’s price target on GeneDx (WGS) to $170 from $160 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for GeneDx.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $155 from $140 at Wells Fargo
- GeneDx price target raised to $200, named 2026 Top Pick at BTIG
- TSLA, META: Cathie Wood Dumps These Two Magnificent 7 Stocks, Doubles Down on Trade Desk (TTD) Instead
- WGS, WRD, IRDM: Cathie Wood Ramps Up Buying in GeneDx and WeRide, Trims Exposure in Iridium stock
- GeneDx price target raised to $160 from $140 at Piper Sandler